GlycanAge: Pioneering Preventative Healthcare

GlycanAge, a biotech startup, secures €3.9 million to revolutionize preventative healthcare with personalized diagnostics. Founded in 2020, the company utilizes glycobiology to provide cutting-edge biological age tests, enabling early health risk prevention strategies. Co-led by LAUNCHub Ventures and Kadmos Capital, the funding will drive GlycanAge's shift towards the broader diagnostics market, empowering individuals to take control of their well-being. With a $4.2 million seed round, GlycanAge aims to provide customers with accurate biological age measurements, paving the way for a healthier future.